Clinical TrialsEli Lilly continues LAE102 clinical trials in the US, which suggests confidence in LAE102’s safety profile.
Drug Mechanism And EfficacyLAE102, based on the ActRII mechanism, could prevent muscle loss, according to clinical results.
Potential Market OpportunitiesPotential license-in offer for LAE002 by Chinese pharma companies could drive share price.